Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target
Score
Olema Pharmaceuticals, Inc. price target
| OLMA | |
|---|---|
| Low | $20.00 |
| Average | $28.33 |
| High | $35.00 |
| Upside vs current price | +274.7% |
The average target of $28.33 is +274.7% versus the current OLMA price of $7.56.
Olema Pharmaceuticals, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 2 |
| Buy | 9 |
| Hold | 1 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
12 analysts cover OLMA.
Olema Pharmaceuticals, Inc. EPS and revenue estimates
OLMA shows the next fiscal years with at least three analysts: 2026 EPS $-2.60, 2027 EPS $-2.90. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-2.60 | $2.25M |
| 2027 | $-2.90 | $8.19M |
Is Olema Pharmaceuticals, Inc. a buy or sell?
Of the 12 analysts covering Olema Pharmaceuticals, Inc., 11 rate it a buy (2 strong buy and 9 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The OLMA consensus label is Buy, beside 11 buy-side ratings and 0 sell-side ratings.
The average target of $28.33 implies +274.7% versus the current price of $7.56.
Those 12 ratings on OLMA are a headcount, and the label on file is Buy.
Reading the Olema Pharmaceuticals, Inc. forecast
The OLMA target range is wide: $20.00 at the low end, $28.33 in the middle, and $35.00 at the top.
Set next to the $7.56 OLMA quote, that average is +274.7%.
Ratings on the Olema Pharmaceuticals, Inc. cluster: 11 of 12 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.
The OLMA EPS path from 2026 ($-2.60) to 2027 ($-2.90) is falling.
Only 12 analysts cover OLMA, so the average rests on a short list.
Olema Pharmaceuticals, Inc. forecast questions
What is the OLMA price target?
The published range for OLMA is $20.00 to $35.00, with an average of $28.33. That average is +274.7% versus the current price of $7.56.
Is Olema Pharmaceuticals, Inc. a buy or sell?
Of the 12 analysts covering Olema Pharmaceuticals, Inc., 11 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, and the OLMA headcount is 11 buy, 1 hold, and 0 sell.
What is the EPS estimate for Olema Pharmaceuticals, Inc.?
Analyst EPS estimates for Olema Pharmaceuticals, Inc.: 2026 $-2.60, 2027 $-2.90.
What is the revenue estimate for Olema Pharmaceuticals, Inc.?
Analyst revenue estimates for Olema Pharmaceuticals, Inc.: 2026 $2.25M, 2027 $8.19M.
How many analysts cover OLMA?
12 analysts cover OLMA. Their consensus on OLMA is Buy, across those 12.